Abstract:Abstract A key aspect of achieving UHC and reducing health inequity is ensuring the timely access to high-quality, safe and effective medicines across the world. The regulatory approval of such products in countries with limited regulatory resources can be lengthy, often compromising patients’ timely access to much-needed medicines. This resource-demanding process extends well beyond marketing authorisation, incl. for post-approval changes. The WHO Collaborative Registration Procedure uses the Stringent Regulatory Authorities’ medicines evaluations (SRA CRP), a procedure that allows National Regulatory Authorities (NRAs) to leverage the work performed by Stringent Regulatory Authorities (SRAs) on scientific evaluations to decide on medical products approvals within their jurisdiction, through the concept of reliance. Reliance allows an authority to leverage the work performed by other authorities, such as scientific evaluations, to decide on medical products approval within their jurisdiction. This reduces duplication of regulatory efforts, resources and time, while maintaining national sovereignty. In the context of these processes, multi-agency partnerships and cross-border collaboration the role of European bodies, and specifically that of the European Medicines Agency (EMA) as a Stringent Regulatory Authority will be explored. The SRA CRP and its pilot has been evaluated, based on data and stakeholders’ perceptions. The evaluation indicates that the procedure delivers on expected objectives and benefits, including shortened timelines (from submission to approval), reduced duplication of efforts and resources (human and financial). It also shows significant and long-term positive impact for the LMICs involved. Additional benefits include greater application of international harmonized standards, an added capacity-building component and an informed and high-quality decision-making at the NRA. The impact of the procedure can be seen through 59 approvals for 16 medicines in 23 countries. The key areas for improvement and recommendations include greater collaboration, communication and transparency between NRAs, applicants, SRAs and WHO, to facilitate interactions and regular sharing of information between stakeholders. It is key to optimise resource utilisation and to leverage synergies, and to this end, a centralized, live platform could be developed to share the status, progress and challenges of applications in real time including information related to post-approval changes. This panel will present the SRA CRP pilots and its evaluation, bringing together experts from regulatory agencies and multilateral bodies to elucidate the current degree and extent of collaboration, whilst attempting to role of the EU and of the EMA in these processes. The panelists will also have an opportunity to take questions from the audience and to discuss the contribution of the EU to global health, incl., timely access for people across the world. Key messages • The SRA CRP facilitates and accelerates the regulatory approval of quality-assured, safe and effective medicines by reliance on SRAs, while maintaining decision-making national sovereignty. • The EU, via the EMA and the EUM4all and SRA CRP mechanisms, promotes international collaboration and reliance pathways for earlier access to medicines and contributing to global public health and UHC. Speakers/Panellists Victoria Palmi European Medicines Agency, Amsterdam, Netherlands Mariana Roldão Santos WHO, Geneve, Switzerland Richard Pilsudski Sanofi, Paris, France

European Scheme to Develop Drugs for Diseases with No Treatment Launched

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Specialists Attack Drug Agency'S Fast Track Approval Scheme

European priority review vouchers for neglected disease product development

NICE to Advise Firms on How to Speed Up NHS Adoption of Their Drugs

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach

First Drug is Approved under Scheme That Gives Patients Access to Unlicensed Medicines

Prospects for Rapid Advances in the Development of New Medicines for Special Medical Needs

Putting meat on the bone: how to fast-track innovative medicines to those who need them and generate data to justify continued use

An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations

Nhs Must Find Ways To Speed Access To New Drugs And Technologies

Government launches scheme to deliver five “breakthrough technologies” a year

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

German Body Calls For Pause In European Plan For Fast Track Drug Approval

Skip pattern approach toward the early access of innovative anticancer drugs

NICE Approves First Drug under the Early Access to Medicines Scheme

Future European health care: cost containment, health care reform and scientific progress in drug research

European Drug Agency Launches Website Giving Open Access to Trial Data.

Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

11.H. Round table: Timely access to quality-assured medicines worldwide